Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study of 2 million AF patients reveals Real-World impact of blood thinners

NCT ID NCT05838664

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study analyzed data from over 2 million people in France with atrial fibrillation (an irregular heart rhythm) to compare outcomes between those who took blood thinners and those who did not. Researchers looked at rates of stroke, major bleeding, and death between 2016 and 2020 using a national health database. The goal was to understand how well these medications work in everyday practice, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral anticoagulants (blood thinners: apixaban, rivaroxaban, dabigatran, warfarin)
What this could lead to
If successful, this study could help doctors better understand the real-world benefits and risks of blood thinners for atrial fibrillation patients, potentially improving treatment guidelines.
What could go wrong
This is a retrospective study using existing data, not a controlled experiment. It can show patterns but cannot prove cause and effect. Results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,140,403 people

The number who actually took part.

Started

Jul 2023

Finished

Sep 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

18 years old AF Patients and older will be included from January 1st, 2016 to December 31st, 2020:

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Identified patients with AF aged 18 years and older at diagnosis of AF Exclusion Criteria: * AF Patients with at least one hospital stays for associated valve disease or valve surgery * Patients treated with an OAC for another indication than AF

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • Pfizer Investigational Site

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.